Browse list of available series in The Biomedical & Life Sciences Collection
Recommend The Biomedical & Life Sciences Collection to your librarian
Request to be kept updated on The Biomedical & Life Sciences Collection
Apply for a free trial of The Biomedical & Life Sciences Collection
View all talks & series with full access

Guest (sample access)

Optional Login with Username


        
> Home  /  Biomedical & Life Sciences  /  Series  /  Human Population Genetics  /  Talk Details
SHARE:   Email via Outlook   Email via Web   Facebook   Twitter   |   more
Close SHARE
Please select one of the methods below to share the following page with your collegues:
The Genetics of Breast and Ovarian Cancer
Blogger Google Reader
Delicious Linked In
Digg MySpace
Favorites PDF Online
Gmail

Hello. As a guest, you do not have full access to this talk. Click the PLAY button below to watch the sample extract. Alternatively, you may login or review methods of obtaining more access.

    SPEAKER(S)

Dr. Piri Welcsh - University of Washington, USA

Piri Welcsh is an Assistant Research Professor in the Department of Medicine, Division of Medical Genetics at the University of Washington. She received her undergraduate training at Marquette University and earned her PhD in molecular biology at The Ohio State University. As a postdoctoral fellow at the University of Texas Southwestern Medical Center in Dallas, she collaborated with Dr. Mary-Claire King on the cloning of BRCA1. She joined Dr. King's lab at the University of Washington in 1996 where she performed studies designed to determine the cellular function of the BRCA1 protein. She continues to collaborate with Dr. King on identifying additional breast cancer predisposing genes. The focus of her independent research is to determine how alterations in the epigenome contribute to breast and ovarian cancer development.

Talk Online Publication: Oct 2007

TOPICS COVERED IN THE GENETICS OF BREAST AND OVARIAN CANCER

General cancer genetics - Tumor suppressor and oncogenes - Knudson's 'two hit' hypothesis - Genetic predisposition to breast and ovarian cancer - How much breast and ovarian cancer is inherited and the causes (genes responsible) - Cancer risk in populations - Factors that affect penetrance - Mutation detection - Risk reduction and prevention strategies

How to cite this talk:
Welcsh, P. (2007), "The Genetics of Breast and Ovarian Cancer", in Cavalli-Sforza, L.L. and Feldman, M. (eds), Human Population Genetics: Evolution and Variation , The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio)

Direct talk access link:
http://hstalks.com/lib.php?t=HST25.1571_1_2&c=252

    DETAILED SLIDE INDEX

1. Introduction
2. Genetics of cancer
3. Oncogenes
4. Tumor suppressor genes
5. Breast cancer "family 0"
6. The two-hit hypothesis
7. How much breast and ovarian cancer is hereditary
8. Hereditary susceptibility causes to ovarian cancer
9. Hereditary susceptibility causes to breast cancer
10. BRCA1 and BRCA2 mutations
11. Lifetime cancer risk in mutation carriers
12. Epidemiology: BRCA1 and BRCA2
13. Founder effect
14. Selected examples of founder mutations
15. BRCA1 and BRCA2 mutations in Ashkenazi Jews
16. Varied penetrance
17. New York breast cancer study (NYBCS)
18. NYBCS family 96: "low incidence family"
19. Family 96: BRCA1 5382insC
20. Relatives with BRCA1\2 mutations: breast cancer
21. Relatives with BRCA1\2 mutations: ovarian cancer
22. Relatives with BRCA1\2 mutations: cancer onset
23. Factors affecting penetrance
24. Factors not significantly associated with age
25. New York breast cancer study conclusions
26. Mutation detection for BRCA1 and BRCA2
27. Inherited large rearrangements in BRCA1\BRCA2
28. Genomic regions of BRCA1 and BRCA2
29. Genetics of breast cancer "mystery families"
30. Inherited breast and ovarian cancer
31. PALB2 1592delT in Finnish breast cancer families
32. PALB2 1592delT: Finnish prostrate cancer family
33. Genes for inherited breast cancer
34. Breast cancer genes and genomic integrity
35. Biology of breast cancer genes
36. Identification of inherited cancer risk
37. Benefits
38. Risk assessment
39. Cancer risk reduction in women
40. Preventive removal of ovaries
41. Women with increased-risk family history
42. END